Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.

Correction to: Respir Res

https://doi.org/10.1186/s12931-018-0916-7

Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.

Reference 24 needs to be amended to 25

The 12-week study needs to be corrected to 8-week study

Corrected text:

This study is the first to compare two LAMA/LABA dual therapies using direct head-to-head data from a randomized, 8-week study [25], which is the most reliable set of data to include within a cost-effectiveness model [25].